Table 3 Efficacy of Pralsetinib in ARROW trial
From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer
Overall (n = 116) | Prior platinum treatment (n = 80) | No prior systemic treatment (n = 26) | Measurable Brain Metastases (n = 9) | |
|---|---|---|---|---|
ORR, % | 65 (5% CI 55–73) | 61 (95% CI 50–72) | 73 (95% CI 52–88) | 55 |
DOR | NR | – | – | – |
DCR, % | 93 (87–97) | 95 (95% CI 88–99) | 88 (9% CI 70–98) | – |